5 notable AI advances presented at RSNA 2020

There was nothing virtual about the interest in AI at the virtual annual meeting of the Radiological Society of North America Nov. 29 to Dec. 5.

Despite the lack of actual foot traffic, more than 105 exhibitors presented AI-specific wares in the virtual AI showcase. That was down from 2019’s pre-COVID 150 or so but still easily beat 2018’s head count, around 75.

Meanwhile the 2020 show’s scientific sessions and press conferences broke several noteworthy developments. Here are links to coverage of five (in no special order):

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.